RHB-204

Drug identity checked against registry records

Also recorded as Clarithromycin 158.3mg, Rifabutin 40mg and Clofazimine 13.3mg

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex DiseaseNCT04616924RedHill Biopharma LimitedPhase 3Terminated2023-08-28Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.